Marc Jenniskens1, Lies Langouche1, Yoo-Mee Vanwijngaerden1, Dieter Mesotten1, Greet Van den Berghe2. 1. Clinical Division and Laboratory of Intensive Care Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. 2. Clinical Division and Laboratory of Intensive Care Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. greet.vandenberghe@med.kuleuven.be.
Abstract
OBJECTIVE: In ICU patients, abnormal liver tests are common. Markers of cholestasis are associated with adverse outcome. Research has focused on the possibility that mild hyperbilirubinemia, instead of indicating inadvertent cholestasis, may be adaptive and beneficial. These new insights are reviewed and integrated in the state-of-the-art knowledge on hepatobiliary alterations during sepsis and other critical illnesses. DATA SOURCES: Relevant publications were searched in Medline with search terms bile, bile acids, cholestasis, critical illness, intensive care, sepsis, alone or in combination. DATA SYNTHESIS: Studies have shown that bilirubin, but also bile acids, the main active constitutes of bile, are increased in plasma of patients with critical illnesses. In particular the conjugated fractions of bilirubin and bile acids are high, indicating that during critical illness the liver is capable of converting these molecules to less toxic forms. In human liver biopsies of prolonged critically ill patients, expression of bile acid excretion pumps towards the bile canaliculi was lower, while alternative transporters towards the systemic circulation were upregulated. Remarkably, in the presence of increased circulating bile acids, expression of enzymes controlling synthesis of bile acids was not suppressed. This suggested loss of feedback inhibition of bile acids synthesis, possibly explained by the observed cytoplasmic retention of the nuclear FXR/RXR heterodimer. As macronutrient restriction during acute critical illness, an intervention that improved outcome, was found to further increase plasma bilirubin while reducing other markers of cholestasis, a potentially protective role of hyperbilirubinemia was suggested. CONCLUSION: The increase in circulating levels of conjugated bile acids and bilirubin in response to acute sepsis/critical illnesses may not necessarily point to cholestasis as a pathophysiological entity. Instead it may be the result of an adaptively altered bile acid production and transport back towards the systemic circulation. How these changes could be beneficial for survival should be further investigated.
OBJECTIVE: In ICU patients, abnormal liver tests are common. Markers of cholestasis are associated with adverse outcome. Research has focused on the possibility that mild hyperbilirubinemia, instead of indicating inadvertent cholestasis, may be adaptive and beneficial. These new insights are reviewed and integrated in the state-of-the-art knowledge on hepatobiliary alterations during sepsis and other critical illnesses. DATA SOURCES: Relevant publications were searched in Medline with search terms bile, bile acids, cholestasis, critical illness, intensive care, sepsis, alone or in combination. DATA SYNTHESIS: Studies have shown that bilirubin, but also bile acids, the main active constitutes of bile, are increased in plasma of patients with critical illnesses. In particular the conjugated fractions of bilirubin and bile acids are high, indicating that during critical illness the liver is capable of converting these molecules to less toxic forms. In human liver biopsies of prolonged critically illpatients, expression of bile acid excretion pumps towards the bile canaliculi was lower, while alternative transporters towards the systemic circulation were upregulated. Remarkably, in the presence of increased circulating bile acids, expression of enzymes controlling synthesis of bile acids was not suppressed. This suggested loss of feedback inhibition of bile acids synthesis, possibly explained by the observed cytoplasmic retention of the nuclear FXR/RXR heterodimer. As macronutrient restriction during acute critical illness, an intervention that improved outcome, was found to further increase plasma bilirubin while reducing other markers of cholestasis, a potentially protective role of hyperbilirubinemia was suggested. CONCLUSION: The increase in circulating levels of conjugated bile acids and bilirubin in response to acute sepsis/critical illnesses may not necessarily point to cholestasis as a pathophysiological entity. Instead it may be the result of an adaptively altered bile acid production and transport back towards the systemic circulation. How these changes could be beneficial for survival should be further investigated.
Authors: V M van Deursen; K Damman; H L Hillege; A P van Beek; D J van Veldhuisen; A A Voors Journal: J Card Fail Date: 2009-09-26 Impact factor: 5.712
Authors: Brian G Harbrecht; Mazen S Zenati; Howard R Doyle; John McMichael; Ricard N Townsend; Keith D Clancy; Andrew B Peitzman Journal: J Trauma Date: 2002-09
Authors: Falk A Gonnert; Peter Recknagel; Ingrid Hilger; Ralf A Claus; Michael Bauer; Andreas Kortgen Journal: Crit Care Date: 2013-04-10 Impact factor: 9.097
Authors: Mabel N Abraham; Alexander P Kelly; Ariel B Brandwein; Tiago D Fernandes; Daniel E Leisman; Matthew D Taylor; Mariana R Brewer; Christine A Capone; Clifford S Deutschman Journal: Shock Date: 2020-08 Impact factor: 3.454
Authors: Chuan Hong; Harrison G Zhang; Sehi L'Yi; Andrew South; Gabriel A Brat; T Cai; Griffin Weber; Paul Avillach; Bryce W Q Tan; Alba Gutiérrez-Sacristán; Clara-Lea Bonzel; Nathan P Palmer; Alberto Malovini; Valentina Tibollo; Yuan Luo; Meghan R Hutch; Molei Liu; Florence Bourgeois; Riccardo Bellazzi; Luca Chiovato; Fernando J Sanz Vidorreta; Trang T Le; Xuan Wang; William Yuan; Antoine Neuraz; Vincent Benoit; Bertrand Moal; Michele Morris; David A Hanauer; Sarah Maidlow; Kavishwar Wagholikar; Shawn Murphy; Hossein Estiri; Adeline Makoudjou; Patric Tippmann; Jeffery Klann; Robert W Follett; Nils Gehlenborg; Gilbert S Omenn; Zongqi Xia; Arianna Dagliati; Shyam Visweswaran; Lav P Patel; Danielle L Mowery; Emily R Schriver; Malarkodi Jebathilagam Samayamuthu; Ramakanth Kavuluru; Sara Lozano-Zahonero; Daniela Zöller; Amelia L M Tan; Byorn W L Tan; Kee Yuan Ngiam; John H Holmes; Petra Schubert; Kelly Cho; Yuk-Lam Ho; Brett K Beaulieu-Jones; Miguel Pedrera-Jiménez; Noelia García-Barrio; Pablo Serrano-Balazote; Isaac Kohane Journal: BMJ Open Date: 2022-06-23 Impact factor: 3.006
Authors: Bryna L Fitzgerald; Claudia R Molins; M Nurul Islam; Barbara Graham; Petronella R Hove; Gary P Wormser; Linden Hu; Laura V Ashton; John T Belisle Journal: J Proteome Res Date: 2020-01-09 Impact factor: 4.466
Authors: Jason Wagner; Victor Garcia-Rodriguez; Abraham Yu; Barbara Dutra; Scott Larson; Brooks Cash; Andrew DuPont; Ahmad Farooq Journal: Sci Rep Date: 2021-05-13 Impact factor: 4.379
Authors: Helle G Olsen; Mads Kjelgaard-Hansen; Pernille Tveden-Nyborg; Malene M Birck; Karsten P Hammelev; Andreas Vegge; Bent Aalbæk; Páll S Leifsson; Henrik E Jensen; Tine Iburg; Peter M H Heegaard; Ole L Nielsen Journal: BMC Res Notes Date: 2016-02-16